EcoDrugPlus

Cholecystokinin A Receptor

Ensembl ID : ENSSCAG00000004827
Gene Symbol: CCKAR
3 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSSCAG00000006237
Gene Symbol: CETP
3 Cross references
137 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Muscarinic 2

Ensembl ID : ENSSCAG00000009921
Gene Symbol: CHRM2
3 Cross references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSSCAG00000007978
Gene Symbol: CHRM3
3 Cross references
255 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSSCAG00000002686
Gene Symbol: CHRM4
3 Cross references
184 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSSCAG00000012059
Gene Symbol: CHRM5
3 Cross references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSSCAG00000012603
Gene Symbol: CHRNA3
3 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSSCAG00000014702
Gene Symbol: CHRNA4
3 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSSCAG00000012910
Gene Symbol: CHRNB2
1 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSSCAG00000012611
Gene Symbol: CHRNB4
3 Cross references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSSCAG00000005008
Gene Symbol: F2R
1 Cross references
312 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSSCAG00000012591
Gene Symbol: F3
3 Cross references
243 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).